Skip to main content

Добре дошли в Janssen България

VISIT JANSSEN GLOBAL

Media Center

Press Releases

Jan 21, 2019

JANSSEN SUBMITS APPLICATION TO EUROPEAN MEDICINES AGENCY SEEKING APPROVAL OF STELARA® (USTEKINUMAB) FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Jan 21, 2019

New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

Jan 17, 2019

Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Dec 23, 2018

Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) Split Dosing Regimen

Dec 06, 2018

Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▼ (ibrutinib)-Based Therapy Across All Patient Populations in CLL

Dec 06, 2018

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced R/R Multiple Myeloma1

View more Press Releases

Media Backgrounders

Janssen Research Global Collaboration

Investing in European Health R&D

Janssen Health Policy Centre

Investing in European Health R&D - Executive Summary

About Xeplion

About Schizophrenia

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

Tweets

Janssen EMEA

@JanssenEMEA

Advanced forms of #BladderCancer significantly impact patients’ quality of life.

10 months 2 weeks ago

Follow us on Twitter

SUBSCRIBE TO OUR YOUTUBE CHANNEL